Kuramoto H.
Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line.
Acta Obstet. Gynaecol. Jpn. 19:47-58(1972)
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)
Fogh J., Wright W.C., Loveless J.D.
of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)
Sekiya S., Takamizawa H.
Effect of anticancer drugs on in vitro survival of cell lines derived from various gynecologic tumors.
Nihon Sanka Fujinka Gakkai Zasshi 33:373-376(1981)
Sekiya S., Kawata M., Inaba N., Takamizawa H.
Studies on marker substances in cell lines derived from various human gynecologic tumors.
Nihon Sanka Fujinka Gakkai Zasshi 34:37-42(1982)
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)
Kurarmoto H., Hamano M., Imai M.
HEC-1 cells.
Hum. Cell 15:81-95(2002)
Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T., Kawaguchi M.
HEC-1 cells: establishment of an in vitro experimental system in endometrial carcinoma.
(In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo (2003)
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R., Zhang W.
Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.
Technol. Cancer Res. Treat. 9:179-189(2010)
Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010)